MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 563118 | Name: Tiracizine HCl

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Tiracizine HCl is an anti-arrhythmia agent.

Chemical Structure

Tiracizine HCl
CAS#78816-67-8

Theoretical Analysis

MedKoo Cat#: 563118

Name: Tiracizine HCl

CAS#: 78816-67-8

Chemical Formula: C21H26ClN3O3

Exact Mass: 403.1663

Molecular Weight: 403.90

Elemental Analysis: C, 62.45; H, 6.49; Cl, 8.78; N, 10.40; O, 11.88

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Tiracizine HCl; Tiracizine Hydrochloride; Bonnecor; AWD-19-166; AWD19166; AWD 19 166;
IUPAC/Chemical Name
ethyl (5-(dimethylglycyl)-10,11-dihydro-5H-dibenzo[b,f]azepin-3-yl)carbamate hydrochloride
InChi Key
XJWABFCDXKZWPV-UHFFFAOYSA-N
InChi Code
InChI=1S/C21H25N3O3.ClH/c1-4-27-21(26)22-17-12-11-16-10-9-15-7-5-6-8-18(15)24(19(16)13-17)20(25)14-23(2)3;/h5-8,11-13H,4,9-10,14H2,1-3H3,(H,22,26);1H
SMILES Code
O=C(CN(C)C)N1C2=C(C=CC(NC(OCC)=O)=C2)CCC3=CC=CC=C13.Cl
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 403.90 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Galenko-Iaroshevskiĭ PA, Khankoeva AI, Uvarov AV, Bartashevich VV, Popov PB, Sirotenko DV, Boldin VB. [Correction of the cardiotoxic effect of the anti-arrhythmia agents with befol, sufan, and their combination]. Biull Eksp Biol Med. 1998 Jun;125(6):641-6. Russian. PubMed PMID: 9693756. 2: Oertel R, Richter K, Gramatté T, Kirch W. Determination of drugs in biological fluids by high-performance liquid chromatography with on-line sample processing. J Chromatogr A. 1998 Feb 27;797(1-2):203-9. PubMed PMID: 9542112. 3: Mishin IuI, Kliachkina IL, Ivashkin VT, Min'kova TI, Bannikova SD. [The anti-arrhythmia action of tiracizine in patients with ischemic heart disease and decreased myocardial contractile function]. Voen Med Zh. 1997 Jun;318(6):44-7. Russian. PubMed PMID: 9412062. 4: Galenko-Iaroshevskiĭ PA, Khankoeva AI, Uvarov AV, Reznikov AIu, Galygo DS, Bartashevich VV. [Comparative anti-arrhythmia activity of befol, lidocaine, and bonnecor]. Biull Eksp Biol Med. 1996 Dec;122(12):665-8. Russian. PubMed PMID: 9280469. 5: Zaslavskaia RM, Mirskiĭ BA, Diagilev II. [The efficacy of anti-arrhythmia therapy with bonnecor in middle-aged and elderly patients]. Klin Med (Mosk). 1996;74(2):30-2. Russian. PubMed PMID: 8772098. 6: Berndt A, Hoffmann C, Richter K, Oertel R, Vierkant A, Siegmund W. Tiracizine disposition in healthy volunteers with reference to the debrisoquine oxidation phenotype. Br J Clin Pharmacol. 1995 Sep;40(3):287-8. PubMed PMID: 8527295; PubMed Central PMCID: PMC1365113. 7: Berndt A, Oertel R, Terhaag B, Richter K, Gramatté T. Pharmacokinetics of the antiarrhythmic agent tiracizine: steady state kinetics in comparison with single-dose kinetics. Biopharm Drug Dispos. 1995 Jul;16(5):427-41. PubMed PMID: 8527691. 8: Németh M, Varró A, Papp JG. Electrophysiological effects of tiracizin and its metabolites in dog cardiac Purkinje fibers. Gen Pharmacol. 1995 Jul;26(4):793-8. PubMed PMID: 7635254. 9: Berndt A, Gramatté T, Oertel R, Terhaag B, Richter K, Kirch W. Day-night variations in the renal excretion of the antiarrhythmic agent tiracizine and its metabolites. Chronobiol Int. 1995 Apr;12(2):135-40. PubMed PMID: 8653799. 10: Berndt A, Oertel R, Richter K, Terhaag B, Gramatté T. [Relative bioavailability of the antiarrhythmia agent, tiracizine and its metabolites]. Arzneimittelforschung. 1995 Mar;45(3):250-3. German. PubMed PMID: 7741778. 11: Fomichev VI, Smerdina IS, Preobrazhenskiĭ DV, Gorshkov VA. [Use of bonnecor in the treatment of ventricular arrhythmia]. Klin Med (Mosk). 1995;73(4):44-6. Russian. PubMed PMID: 7474818. 12: Berndt A, Gramatté T, Oertel R, Richter K, Terhaag B, Kirch W. Dose dependent tiracizine disposition in healthy volunteers: serum and urine kinetics and dose related ECG-changes. Eur J Drug Metab Pharmacokinet. 1994 Oct-Dec;19(4):359-68. PubMed PMID: 7737238. 13: Berndt A, Oertel R, Richter K, Gramatté T. Food Enhances Bioavailability of the New Antiarrhythmic Agent Tiracizine by Affecting its Hepatic First-Pass Metabolism: Evidence by Serum and Urine Metabolite Kinetics. Am J Ther. 1994 Jun;1(1):22-29. PubMed PMID: 11835063. 14: Paliani-Katsitadze NSh, Berdiaev SIu, Turilova AI, Kaverina NV, Likhosherstov AM. [A comparative study of the antiarrhythmic action of bonnecor and the mesidide derivatives of alpha-azacycloalkane carboxylic acids]. Eksp Klin Farmakol. 1994 May-Jun;57(3):15-7. Russian. PubMed PMID: 8049618. 15: Parkhomenko AN, Stepanenko AP, Beziuk NN, Nagnybeda EN, Deiak SI. [The efficacy of bonnecor in refractory ventricular tachycardia in a patient with ischemic heart disease]. Lik Sprava. 1994 Feb;(2):90-2. Russian. PubMed PMID: 8073734. 16: Stejfa M, Zeman K, Groch L, Bytesník J, Krausová R. [Tiracizine in the treatment of ventricular arrhythmia (preliminary study)]. Vnitr Lek. 1993 Jun;39(6):549-53. Czech. PubMed PMID: 8212608. 17: Smerdina IS, Fomichev VI, Nesvetov VN, Gorshkov VA, Preobrazhenskiĭ DV. [The pharmacodynamics of the new anti-arrhythmia preparation bonnecor based on the data from an acute drug test]. Kardiologiia. 1993;33(7):11-4, 3. Russian. PubMed PMID: 8309173. 18: Denisova SV, Sapozhkov AV. [The effect of bonnecor on blood coagulability and thrombocyte aggregation in transient myocardial ischemia]. Eksp Klin Farmakol. 1992 Nov-Dec;55(6):29-31. Russian. PubMed PMID: 1305870. 19: Kobrin VI, Vostrikov VA. [Effects of bonnecor on transmembrane potentials of cardiomyocytes of the ventricular contractile myocardium of the intact heart and ventricular fibrillation]. Kardiologiia. 1992 Jun;32(6):61-3. Russian. PubMed PMID: 1405299. 20: Kaverina NV, Sokolov SF. Pharmacology and clinical use of a new group of antiarrhythmic drugs: derivatives of tricyclic nitrogen-containing systems. Pharmacol Res. 1992 Apr;25(3):217-25. Review. PubMed PMID: 1518765.

View History

Tiospirone

Tiospirone

Featured